Eli Lilly’s stock surged 3.4% after the company released upbeat financial results for its fourth quarter. Despite missing sales forecasts for its popular weight-loss and diabetes drugs, the company’s overall sales rose 45%, driven by strong demand for Mounjaro.
Mounjaro, a type 2 diabetes treatment, generated $3.53 billion in sales, up 124% from last year. Zepbound, another obesity treatment, saw its sales more modestly rise 101% to $1.91 billion. In contrast, Trulicity’s sales tumbled 26% to $1.25 billion.
For the full year 2025, Eli Lilly expects $58 billion to $61 billion in sales and adjusted earnings of $22.50 to $24 per share. This outlook tops analysts’ forecasts and reflects expectations for continued growth from Mounjaro and Zepbound, as well as a decline in Trulicity volumes.
Source: https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q4-2024